Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

Not Applicable

Completed

• Conditions: Schizophrenia; Suicide
• Interventions: Behavioral: Enhanced Treatment as Usual; Behavioral: Coping Long-term with Active Suicide Program for Schizophrenia

• Registration Number: NCT04221269
• Lead Sponsor: Butler Hospital

Brief Summary

The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-01-06
• Study First Submitted QC: 2020-01-06
• Study First Posted: 2020-01-09
• Study Start: 2020-12-01
• Primary Completion: 2023-06-01
• Study Completion: 2023-06-01
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-10
• Last Update Posted: 2023-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• suicidal thoughts or behaviors prior to hospital admission
• diagnosis of a schizophrenia-spectrum disorder
• receiving pharmacotherapy
• 18 years or older
• speaks/reads English

Exclusion Criteria

• psychosis due to substance use or medical condition
• lack of phone access
• discharge to long-term facility

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Enhanced Treatment as Usual	Enhanced Treatment as Usual	Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
Coping Long-term with Active Suicide Program for Schizophrenia	Enhanced Treatment as Usual	Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
Coping Long-term with Active Suicide Program for Schizophrenia	Coping Long-term with Active Suicide Program for Schizophrenia	Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.

Primary Outcome Measures

Name	Time	Method
Client Satisfaction Questionnaire	6 months	The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.

Secondary Outcome Measures

Name	Time	Method
Columbia Suicide Severity Rating Scale	6 months	The Columbia Suicide Severity Rating Scale is an interviewer-rated measure of suicidal thoughts and behaviors. The total score (sum of items) will be used and ranges from 2 to 25 with higher scores indicating higher suicidal thoughts and behaviors.

Trial Locations

Locations (1)

Butler Hospital; 🇺🇸 Providence, Rhode Island, United States